New company co-founded by Rice faculty member aims to move beyond symptom management in preeclampsia

Emvena Therapeutics, a biotechnology company co-founded by Rice University faculty member Kelsey Swingle, launched with investment from the PxB Fund. The company is developing a treatment for preeclampsia; the article excerpt provides no investment amount, development milestones, or clinical data.